News

In the phase 3 PERSEUS trial, BTK inhibitor tolebrutinib did not significantly reduce disability progression compared with placebo in patients with primary progressive multiple sclerosis.

The assistant professor of medicine at the University of Toronto discussed whether multiple sclerosis can develop prior to Epstein–Barr virus infection and what new population data reveal about the long-standing causality debate. [WATCH TIME: 4 minutes]

Catch up on any of the neurology headlines you may have missed in January 2026, compiled into 1 place by the NeurologyLive® team.

New results presented at ACTRIMS showed that in the phase 3 FENtrepid study, fenebrutinib was noninferior to ocrelizumab in reducing disability progression in primary progressive multiple sclerosis.

Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, demonstrated efficacy in children and adolescents with episodic migraine in full data release.

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis provided background on a study presented at ACTRIMS 2026 focused on patient-reported barriers to timely multiple sclerosis treatment initiation. [WATCH TIME: 4 minutes]

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

The FDA issued a CRL for gene therapy RGX-121 in Hunter syndrome, citing trial design and biomarker doubts; Regenxbio seeks a meeting with the agency and resubmission.

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents for International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

The associate professor of neurology at the University of California, San Francisco discussed the evolving approach to remyelination in patients with MS at the 2026 ACTRIMS Forum. [WATCH TIME: 3 minutes]

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

The professor of neurology at Cleveland Clinic discussed how evolving imaging and biological insights have reshaped the way clinicians define and talk about multiple sclerosis. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

The senior research investigator at the New York Stem Cell Foundation discussed how human iPSC-based models can help dissect the cellular mechanisms underlying PIRA and progressive disability in multiple sclerosis. [WATCH TIME: 3 minutes]

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing